Video

RVL Pharmaceuticals: Shifting toward ocular aesthetics

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial
June 11th 2025

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids
June 9th 2025

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis
June 8th 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis

Q&A: The ELEVATUM Study with J. Fernando Arevalo
June 7th 2025

Q&A: The ELEVATUM Study with J. Fernando Arevalo

© 2025 MJH Life Sciences

All rights reserved.